| Title | The effect of Orlistat on blood glucose and body weight in an onset diabetic rat model | ||
| Authors | M. Mironidou-Tzouveleki1, A. Anogeianaki2, Ch. Dokos1, D. Koutsonikolas2, J. Liagouris2 and G. Anogianakis2
1. A’ Laboratory of Pharmacology, 2. Department of Experimental Physiology, Medical School, Aristotle University, Thessaloniki, Greece |
||
| Citation | Mironidou-Tzouveleki, M., Anogeianaki, A., Dokos, C., Koutsonikolas, D., Liagouris, J. et al.: The effect of Orlistat on blood glucose and body weight in an onset diabetic rat model, Epitheorese Klin. Farmakol. Farmakokinet. 22(2): 256-258 (2008) | ||
| Publication Date | 23-25 May 2008 | ||
| Full Text Language | English | ||
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
||
| Keywords | Diabetes mellitus, Orlistat, body weight, glucose, diabetes mellitus type 1, diabetes mellitus type 2. | ||
| Other Terms | Review article | ||
| Summary | Diabetes mellitus is an important disease of western societies. Patients with type 2 diabetes mellitus often present with dislipidemic disorders such as atherosclerosis. Often, these patients transit to insulin requiring diabetes. Recent studies indicate the use of Orlistat, a gastrointestinal lipase inhibitor, for the prevention of type 2 diabetes. This study examines the effect of Orlistat on body weight and blood glucose levels in a type 1 diabetic animal model. Streptozotocin solution (60mg/kg) was administered to male Wistar rats at the age of 3½ months. Following confirmation of diabetes, the experimental animals were randomly di-vided into two equal groups: a group with no Orlistat nutrition (control) and a group with Orlistat nutrition (20 mg/kg mixed with food). Blood glucose and body weight were measured daily for 2 weeks. Our results indicate that there is a statistically significant decrease (p<0.05) in the average value of blood glucose levels (0.57 mg/dl) and of body weight (52.56 gr) in the Orlistat nutrition group (group 2). Orlistat, therefore, may not only be an unlabelled regimen used, as an anti-obesity drug, for the prevention of type 2 diabetes mellitus but it may also prevent the transition of patients to insulin dependent diabetes mellitus. | ||
| References | 1. Mironidou-Tzouveleki M., Dokos Ch.: Combination of lovastatin and Orlistat: dual therapy strategy in dyslipidemic syndromes of diabetes type II patients. Epitheor. Klin. Farmakol. Farmakokinet. 25: 135-144 (2007)
2. Mulder H., Yang S., Winzell S.M., Holm C., Ahren B.: Inhibition of lipase activity and lipolysis in rat islets reduces insulin secretion. Diabetes 53: 122-128 (2004) 3. Cohn G., Valdes G., Gapuzzi D.M.: Pathophysiology and treatment of dyslipidemia of insulin resistance. Curr. Cardiol. Rep. 3: 416-23 (2001) 4. Neslon H.R., Miles M.J.: The use of Orlistat in the treatment of obesity, dysilpidemia and type 2 diabetes. Exp. Opin. Pharmacother. 6: 2483-2491 (2005) 5. Ueshima K., Akihisa-Umeno H., Nagayoshi A., Takakura S., Matsuo M., Mutoh S.: A gastrointestinal lipase inhibitor reduces progression of atherosclerosis in mice fed a western-type diet. Eur. J. Pharmacol. 501: 137-142 (2004) 6. Liberopoulos E.N., Tsouli S., Mikhailidis D.P., Elisaf M.S.: Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr. Drug Targets 7: 211-228 (2006) 7. Ellsworth J.A., Oliver M.L.: Mosby’s 2007 Medical Drug Reference. Elsevier Mosby, Philadelphia, 2007 |
||
| Relative Papers | |||
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2008 – ANNUAL SUBSCRIPTION 2008 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|